![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 23, 2023 3:41:53 PM
And.... over that period of time standard of care (SOC) continued to improve. So biotech therapies during their FDA studies were constantly competing against improving SOC. IMO it was improving SOC is what took the legs out of most biotech FDA covid studies. As far as I could tell, most FDA studies for covid did not 100% decouple their primary endpoints from SOC. Investors who made a lot of $$ on the covid biotech sector did so by selling 'on the hype'. Those that lost $$ typically were those that held their shares down to the end (FDA trial completions).
Now RVVTF must dump/dilute more shares to keep paying their high compensation packages. The O/S and float will continue to grow. I now only see one undesirable outcome for this when MF and other officers realize that they need to re-energize this cash cow machine while they continue to pursue the DREAM of actually generating sales from a real product. Shroom sales just won't cut it IMO.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM